Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer

Tailwinds' Take: while this news comes suddenly and will likely cause some selling in the stock, we view it as constructive. Mark Day has...

Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform...

Tailwinds' Take: Bioasis appears to have done the necessary pre-clinical work to attract interest from partners. While still early stage, it's apparent that the...

Tailwinds Top 8 Surprises for 2019

Every year for the past 36 years, Byron Wien has put out a list of “Top 10 Surprises” for the...

Bioasis to Present at Investor & Industry Conferences in January 2019

Tailwinds' Take: having emerged from their silent period, Bioasis appears to be very excited about the data they are generating as they...

Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors

GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM  platform technology for the delivery of...

What To Put In Your Stockings: December Preview

This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least,...

Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with...

Tailwinds' Take: this long awaited news is significant for Bioasis and should spark relief in the shares. Expect to see the Company move towards...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena

Tailwinds' Take: a long anticipated licensing deal is likely a major sigh of relief for shares of BIOAF. While small in size, a $1M...

Bioasis Announces Investor Relations Service Agreement with Stern IR

GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB)...

Bioasis Announces Closing of Previously Disclosed Private Placement

Bioasis Technologies (TSX.V:BTI; OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier...

Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 ™-001...

Tailwinds' Take: This is excellent progress. If it translates into human data, a decent probability, it could be huge. Once they get properly funded...

Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate...

RICHMOND, British Columbia & GUILFORD, Conn. & DURHAM, N.C.–(Business Wire)– Bioasis Technologies, Inc . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the...

Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack...

Tailwinds' Take: Scientists of this caliber don't join SABs unless there's something exciting going on. We eagerly anticipate the release of Non-Human Primate data...

Bioasis Announces Publication of Independent Validation of the Company’s xB3 ™ Platform Technology

Tailwinds' Take: Great news! xB3 is poised to be a game-changing platform for treatment of CNS diseases. Still early stage, but the opportunity deserves...

Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of...

Tailwinds' Take: having a manufacturing partner is a key step towards clinical development of their drug candidates. With their recent financing, which we believe...

With Earnings Season Over, Which Stocks Surprised Us?

Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not...

Bioasis Announces Closing of First Tranche of Previously Disclosed Private Placement

Tailwinds' Take: the closing of this private placement is a key catalyst for Bioasis shares. We have been adding in the Tailwinds portfolios and...

Bioasis: Prepping for Financing, but Buying Opportunity Awaits

When I removed Bioasis from the Tailwinds Select Portfolio, it was with great reluctance. This is a Company that I believe has groundbreaking, lifesaving,...

Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline...

VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.